乐普LEPU品牌怎么样 申请店铺

创立于1999年，集产品研发、生产、销售于一体，专业从事植介入诊疗器械及设备领域的医疗产品产业集团，其心血管病植介入诊疗器械在业内颇具影响力

乐普（北京）医疗器械股份有限公司（简称乐普医疗集团）创立于1999年，股份制集团上市公司（股票代码300003），公司销售网络遍布全中国及95个国家和地区，年营业收入46亿元人民币。 通过坚持技术创新、合作共赢的发展之路，乐普医疗集团正努力建立四位一体的心血管全产业链平台型企业。

乐普（北京）医疗器械股份有限公司创立于1999年，总部位于北京市中关村科技园区昌平园。公司是从事冠状动脉药物支架、先心封堵器、心脏瓣膜、造影机等心血管疾病植介入诊疗器械及设备产品研发、生产与销售的中外合资央企控股企业，是2009年在深交所创业板上市的28家企业之一。公司目前拥有国内外8家子公司，产品临床应用覆盖全国1200家以上心脏诊疗中心，已发展成为国内从事的心血管病植介入诊疗器械与设备的医疗产品产业集团。

乐普公司集合了材料、机械、电子、精密加工、临床医学等各类专业人才，拥有一支在产品研发、质量控制、临床验证、市场开拓、企业管理等方面专业的经验丰富的人才队伍。研制开发涵盖：冠心病、结构性心脏病、心脏节律、预先和术后诊断及诊疗设备五大领域的植介入产品，取得了一系列具有国内、国际水平的研究成果。是国内规模较大的也是拥有多种技术特点药物支架产品的制造企业，是亚洲较大的人工心脏瓣膜制造企业，是国内心脏起搏器的先行者，是国内心脏封堵器、血管造影机的市场佼佼者，是国内研制肾动脉射频消融导管的企业。

乐普公司疗创立以来，先后承担了国家发改委高技术产业化示范工程项目、国家科技部863计划发展项目、科技支撑计划项目等几十项国家重大课题。2013年，以乐普公司为依托单位，组建了“国家心脏病植介入诊疗器械及设备工程技术研究中心”，将进一步推动建设国家心脏病植介入诊疗器械及设备技术创新、产业化和人才聚集的平台，攻克一系列行业发展的核心技术和核心工艺，推动我国心脏病植介入医疗事业的迅速发展。我们秉承“以科技的力量，从心点燃生命的光辉”，为广大医护工作者提供更好更强的医疗产品与技术，使更多心血管病患者能够用得上用得起中国自己的医疗技术和产品。

Founded in 1999, it is a medical product industry group integrating product R & D, production and sales, specializing in the field of interventional devices and equipment. Its cardiovascular interventional devices have great influence in the industry. Lepu (Beijing) Medical Devices Co., Ltd. (referred to as Lepu medical group) was founded in 1999. The joint stock group listed company (Stock Code: 300003) ）The company's sales network covers all over China and 95 countries and regions, with an annual operating revenue of 4.6 billion yuan. By adhering to the development path of technological innovation and win-win cooperation, Lepu medical group is striving to establish a platform enterprise of four in one cardiovascular industry chain. Lepu (Beijing) medical equipment Co., Ltd. was founded in 1999 and its headquarter is located in Changping Park, Zhongguancun Science and Technology Park, Beijing. The company is a Sino foreign joint-venture state-owned enterprise holding the R & D, production and sales of cardiovascular disease interventional devices and equipment products, such as coronary drug stent, precordial occluder, heart valve and contrast machine. It is one of the 28 enterprises listed on the growth enterprise market of Shenzhen Stock Exchange in 2009. At present, the company has 8 subsidiaries at home and abroad, with clinical application covering more than 1200 cardiac diagnosis and treatment centers across the country, and has developed into a domestic medical product industry group engaged in cardiovascular interventional diagnosis and treatment equipment and equipment. Lepu company has gathered all kinds of professional talents in materials, machinery, electronics, precision processing, clinical medicine, etc., and has a professional team with rich experience in product research and development, quality control, clinical verification, market development, enterprise management, etc. The research and development covers five fields: coronary heart disease, structural heart disease, heart rhythm, pre and post-operative diagnosis and treatment equipment, and a series of research results with domestic and international level have been achieved. It is a large-scale manufacturing enterprise with a variety of technical characteristics of drug stent products in China, a large artificial heart valve manufacturing enterprise in Asia, a pioneer in domestic cardiac pacemaker, a market leader in domestic cardiac occluder and angiograph, and a domestic enterprise in the research and development of renal artery radiofrequency catheter ablation. Since its establishment, Lepu company has successively undertaken dozens of national major projects, such as the high-tech industrialization demonstration project of the national development and Reform Commission, the 863 program development project of the Ministry of science and technology, and the science and technology support program project. In 2013, with Lepu company as the supporting unit, the "National Center for engineering and technology research of heart disease plant intervention diagnosis and treatment equipment and equipment" was established, which will further promote the construction of a national platform for innovation, industrialization and talent accumulation of heart disease plant intervention diagnosis and treatment equipment and equipment, attack a series of core technologies and core processes for industry development, and promote China's heart disease plant intervention medical affairs The rapid development of the industry. We adhere to the principle of "lighting up the brilliance of life from the heart with the power of science and technology" to provide better and stronger medical products and technologies for medical workers, so that more patients with cardiovascular diseases can use their own medical technologies and products in China.

本文链接： https://brand.waitui.com/56660df8a.html 联系电话：01080120666